Skip to main content

Advertisement

Table 1 Baseline characteristics of the investigated subcohort

From: Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

Biomarker population N %
Age   
Mean 64.15 years   
Range 35–82 years   
≤60 y 58 28.9
>60 y 143 71.1
Sex   
Female 78 38.8
Male 123 61.2
Treatment arm   
FUFOX 105 52.2
CAPOX 96 47.8
Localization of primary tumor   
Colon 131 65.2
Rectum 61 30.3
n.k. 9 4,5
T stage at initial diagnosis   
T1 1 0.4
T2 15 7.5
T3 132 65.7
T4 49 24.4
n.k. 4 2.0
N stage at initial diagnosis   
N0 46 22.9
N1 57 28.3
N2 89 44.3
n.k. 9 4.5
M stage at initial diagnosis   
M0* 59 29.4
M1 115 57.2
n.k. 27 13.4
  1. *M0 indicates metachronous metastatic disease at initial diagnosis of CRC, M1 indicates synchronous metastatic disease at initial diagnosis of CRC. n.k. = not known – there were no data available.